- Home
- VOXR vs AUTL Comparison
VOXR vs AUTL Comparison
Compare VOXR & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOXR | AUTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.5M | 431.2M |
| IPO Year | 2022 | 2025 |
Fundamental Metrics
Financial Performance| Metric | VOXR | AUTL |
|---|---|---|
| Price | $5.40 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 508.4K | ★ 1.4M |
| Earning Date | 02-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.97% | N/A |
| EPS Growth | N/A | ★ 28.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $39.87 | $669.62 |
| Revenue Next Year | $90.76 | $79.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $2.59 | $1.11 |
| 52 Week High | $6.59 | $2.70 |
Technical Indicators
Market Signals| Indicator | VOXR | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 43.77 |
| Support Level | $4.76 | $1.45 |
| Resistance Level | $5.48 | $1.52 |
| Average True Range (ATR) | 0.37 | 0.09 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 3.23 | 13.51 |
Price Performance
Historical ComparisonAbout VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.